Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,430.93
(
-0.94%
)
US TECH 100
28,418.40
(
-1.30%
)
Dow Jones
49,720.94
(
-0.68%
)
Brent Oil
106.29
(
2.02%
)
Bitcoin
79,080.01
(
-2.44%
)
News Focus
News Focus
Post# of 257570
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122985
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: iwfal post# 150608

Monday, 10/15/2012 4:29:46 PM

Monday, October 15, 2012 4:29:46 PM

Post# of 257570
The late relapses you’re referring to occurred in the PILOT study, which tested ABT-450/r + ABT-072 (a non-nuke) + ribavirin; i.e. it had no NS5A inhibitor. The study we’re discussing today, called AVIATOR, tested ABT-450/r + ABT-267 (a newer non-nuke than ABT-072) + ABT-333 (NS5A) + ribavirin.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today